Compare
AbbVie Inc. vs Abbott Laboratories vs Teva Pharmaceutical Industries Ltd vs Regeneron Pharmaceuticals, Inc.
| Latest fiscal year | AbbVie Inc. ABBV | Abbott Laboratories ABT | Teva Pharmaceutical Industries Ltd TEVA | Regeneron Pharmaceuticals, Inc. REGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $61.16B | $44.33B | $17.26B | $14.34B |
| Revenue growth (YoY) | +8.6% | +5.7% | +4.3% | +1.0% |
| Gross margin | 70.2% (computed) | 56.4% (computed) | 51.8% | n/a |
| Operating margin | 24.6% | 18.2% | 12.5% | 24.9% |
| Net margin | 6.9% | 14.7% | 8.2% | 31.4% |
| Net income | $4.23B | $6.52B | $1.41B | $4.50B |
| EPS (Diluted) | $2.36 | $3.72 | $1.21 | $41.48 |
| Operating cash flow | $19.03B | $9.57B | $1.65B | $4.98B |
| Free cash flow | $17.82B | $7.39B | $1.15B | $4.08B |
| Cash & equivalents | $5.23B | $8.52B | $3.56B | $3.12B |
| Total assets | $133.96B | $86.71B | $40.75B | $40.56B |
| Total liabilities | n/a | n/a | $32.83B | $9.30B |
| Shareholders' equity | -$3.27B | $52.13B | $7.91B | $31.26B |
| Return on year-end equity | n/a | 12.5% | 17.8% | 14.4% |
| Shares outstanding | n/a | n/a | n/a | n/a |
Revenue, most recent five fiscal years
| Fiscal year | AbbVie Inc. | Abbott Laboratories | Teva Pharmaceutical Industries Ltd | Regeneron Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $61.16B Ended 2025-12-31 | $44.33B Ended 2025-12-31 | $17.26B Ended 2025-12-31 | $14.34B Ended 2025-12-31 |
| 1 year earlier | $56.33B Ended 2024-12-31 | $41.95B Ended 2024-12-31 | $16.54B Ended 2024-12-31 | $14.20B Ended 2024-12-31 |
| 2 years earlier | $54.32B Ended 2023-12-31 | $40.11B Ended 2023-12-31 | $15.85B Ended 2023-12-31 | $13.12B Ended 2023-12-31 |
| 3 years earlier | $58.05B Ended 2022-12-31 | $43.65B Ended 2022-12-31 | $14.93B Ended 2022-12-31 | $12.17B Ended 2022-12-31 |
| 4 years earlier | $56.20B Ended 2021-12-31 | $43.08B Ended 2021-12-31 | $15.88B Ended 2021-12-31 | $16.07B Ended 2021-12-31 |